QNTM Quantum BioPharma Limited Forward Price-to-Revenue Multiple
The creation of a diversified biopharmaceutical environment with a closed-loop production cycle has catalyzed current transformations for Quantum BioPharma Ltd (QNTM). The forward P/S trajectory clearly visualizes these processes, with serving as the current metric level. Consequently, Quantum BioPharma Ltd (QNTM) is developing neuroprotective formulas and analgesics while simultaneously conducting an internal asset review to reduce costs and align the profitability of its niche segments.
Analytical breakdowns for Quantum BioPharma Corp (QNTM)
- market price and analyst price targets:
- market capitalization data:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Quantum BioPharma Ltd|QNTM - Long-Term Loans to Capital Ratio|Short-Term Debt to Equity Ratio Quantum BioPharma Ltd|QNTM - Company Aggregate Debts|Debt to Book Capitalization Ratio Quantum BioPharma Corp|QNTM - Company Long-Term Liabilities|Company Current Liabilities Quantum BioPharma|Quick Ratio quantumbiopharma.com
- financial results and valuation multiples details:
QNTM - Company Net Income|Projected Future Earnings Quantum BioPharma Ltd|QNTM - Business Payback Period|Future Price to Earnings Quantum BioPharma Limited|QNTM - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Quantum BioPharma Corp|QNTM - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) Quantum BioPharma|QNTM - Earnings per share for the trailing year|Quarterly EPS earnings growth quantumbiopharma.com|QNTM - Earnings growth in current year|Net earnings per share growth forecast for next year Quantum BioPharma Ltd
- total revenue and sales volume data:
Fundamental company analysis:QNTM (Quantum BioPharma)
The integration of its own R&D and production facilities along with B2B distribution into the Quantum BioPharma Ltd (QNTM) ecosystem directly impacts expected revenue dynamics. By analyzing the company's forward P/S ratio, an investor compares market capitalization with projected sales volume, which allows for the determination of the asset's overvaluation and the balancing of capital risks against the long-term growth potential of the biopharmaceutical business.
Competitors of Quantum BioPharma Ltd (QNTM)
Price-to-Projected Revenue Ratio Haleon HLN|Projected Price to Revenue Kenvue Inc|VRNA: Forward Price-to-Revenue Multiple|MENS - Forward P/S Multiple|LGND: Forward P/S Multiple|amneal.com (AMRX) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Perrigo|Market Cap to Projected Revenue ALVO (Alvotech S.A.)|Forward Price-to-Revenue Multiple LQDA (Liquidia Technologies)|Price to Expected Revenue Ratio GLPG|ANI Pharmaceuticals - Forward Price-to-Revenue Multiple|Forward P/S Multiple mannkindcorp.com MNKD|AMPH - Price-to-Projected Revenue Ratio|Pacira Pharmaceuticals (PCRX) - Forward Price-to-Revenue Multiple|SPRY (ARS Pharma) - Forward Price-to-Revenue Multiple|Theravance Corp - Forward Price to Sales|AQST (Aquestive Therapeutics) - Forward P/S Multiple|Price-to-Projected Revenue Ratio SCPH|Forward P/S Multiple TECX|Market Cap to Expected Sales Ratio Tonix Pharma|Price-to-Projected Revenue Ratio China SXT Pharmaceuticals, Inc. SXTC|Eupraxia Pharmaceuticals, Inc. (EPRX) - Market Cap to Future Revenue Ratio|BHST - Price-to-Projected Revenue Ratio|Future Price to Revenue EXOZ|ORMP: Forward P/S Multiple|Entera Bio - Forward Price to Sales|HYFT (MindWalk) - Forward P/S Multiple|Forward P/S Multiple ABVC BioPharma, Inc|Price-to-Projected Revenue Ratio Cumberland Pharmaceuticals (CPIX)|FGEN (fibrogen.com) - Forward Price to Sales|Price-to-Projected Revenue Ratio Telomir Pharmaceuticals, Inc. TELO|RANI - Forward Price-to-Revenue Multiple|Synergy CHC Corporation - Forward P/S Multiple|RLYB - Forward P/S Multiple|LEXX (lexariabioscience.com) - Forward Price-to-Revenue Multiple|pulmatrix.com - Forward Price to Sales|Price-to-Projected Revenue Ratio Pheton Holdings Limited|Price-to-Projected Revenue Ratio APM|Forward Price-to-Revenue Multiple LYRA (Lyra Therapeutics, Inc)|Price to Expected Revenue Ratio IBO|Forward P/S Multiple TNFA (TNF Pharmaceuticals, Inc.)|YCBD: Market Cap to Projected Revenue|PRFX - Price-to-Projected Revenue Ratio|Projected Price to Revenue Altamira Therapeutics (CYTO)|Lipella (LIPO) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue OPTN|Forward Price-to-Revenue Multiple PIRS|PROC (procapsgroup.com) - Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio Petros Pharmaceuticals, Inc. (PTPI)|Forward Price-to-Revenue Multiple Qilian International Holding Group QLI|Price-to-Projected Revenue Ratio ACELYRIN, Inc. SLRN|TFFP (TFF Pharmaceuticals, Inc) - Future Price to Revenue
